Jason Dictenberg is an entrepreneur and scientist with over 15 years of experience in the life sciences sector, with strong business and leadership skills in biopharmaceutical strategy and operational planning.
He holds a BA in molecular cell biology and mathematics from Brandeis University, where his research into lipid biochemistry led to the discovery of the hyper-cholesterolemic effects of trans-fatty acids, and the formulation of EarthBalance Blends for improved human cardiology and cholesterol homeostasis.
Dr. Dictenberg holds a PhD in Molecular Medicine from the University of Massachusetts Medical Center, where his oncology discovery work led to groundbreaking function and new target strategy for the animal cell division organelle, the centrosome.
During a fellowship at Albert Einstein College of Medicine (AECOM), he directed research on the human genetics of learning and memory and raised both private and public funds to investigate pharmacologic regulation of gene expression in neurologic disease, including autism, Alzheimer's disease, epilepsy and psychiatric mood disorders.
He has raised millions of dollars to investigate cancer biology and developmental brain disorders, including Federal grants from the National Institutes of Health and National Science Foundation.
Prior to AccelBio, he previously held faculty positions and served as a consultant and director to several biopharmaceutical companies, healthcare fund management firms and academic centers including City University, Weill Cornell Medical School, Amylin Pharmaceuticals, The Scripps Research Institute, Albert Einstein College of Medicine, and Array Capital.
Dr. Dictenberg is an author of over 100 primary research papers, abstracts and conference presentations, and is the recipient of the Albert Einstein Scholar Award from AECOM, as well as the Young Investigator Award from the International Society for Developmental Neuroscience.